FEV1 response to albuterol is not affected by inhaled human insulin (Exubera®) use in subjects with mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 840s Year: 2006
Effect of duration of smoking cessation on the absorption of inhaled human insulin (Exubera®) Source: Eur Respir J 2006; 28: Suppl. 50, 390s Year: 2006
Pulmonary function of inhaled human insulin (Exubera®) in patients with type 1 diabetes: results from a 2-year study using standardized methodology Source: Eur Respir J 2006; 28: Suppl. 50, 613s Year: 2006
Pulmonary function of inhaled human insulin (Exubera®) in patients with type 2 diabetes: results from a 2-year study using standardized methodology Source: Eur Respir J 2006; 28: Suppl. 50, 742s Year: 2006
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Time course of insulin antibody response during inhaled insulin therapy does not correlate with changes in pulmonary function Source: Eur Respir J 2005; 26: Suppl. 49, 375s Year: 2005
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD Source: Eur Respir J, 54 (6) 1900521; 10.1183/13993003.00521-2019 Year: 2019
Influence of basal FEV1 on the response to bronchodilator agents in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
The lung microbiota changes associated with inhaled corticosteroid and azithromycin in murine model of COPD Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018
Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Effect of acute passive cigarette smoke exposure on the single-dose pharmacokinetics of inhaled human insulin (Exubera®) Source: Eur Respir J 2006; 28: Suppl. 50, 800s Year: 2006
Normal lung function and absence of bronchodilator response in children with stable, controlled asthma using inhaled corticosteroids Source: Annual Congress 2006 - New features of paediatric asthma Year: 2006
Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis) Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018
Effect of inhaled human insulin (EXUBERA®; EXU) vs subcutaneous insulin (SC) on lung lining fluid constituents in adults with type 1 diabetes mellitus (T1DM) Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
Inhaled formulation of angiotensin-(1-7) produces lung protective effects in a model of chronic asthma. Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018
Evaluating the effects of inhaled corticosteroid on insulin sensitivity in asthmatic patients Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease Source: Annual Congress 2006 - Recent advances in the treatment of COPD Year: 2006
Oral or inhaled corticosteroids for patients with chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=281 Year: 2006